Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - compresse rivestite con film - venetoclaxum 10 mg, excipiens pro compresso haze. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - compresse rivestite con film - venetoclaxum 50 mg, excipiens pro compresso haze. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - compresse rivestite con film - venetoclaxum 100 mg, excipiens pro compresso haze. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocitica, cronica, b-cell - agenti antineoplastici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - nirmatrelvirum, ritonavirum - compresse rivestite con film - a): nirmatrelvirum 150 mg, cellulosum microcristallinum, lactosum monohydricum 185 mg, carmellosum natricum conexum, silica colloidalis anhydrica, natrii stearylis fumaras, Überzug: hypromellosum, e 171, macrogolum 400, e 172 (rubrum), pro compresso obducto corresp. natrium 0.99 mg. b): ritonavirum 100 mg, copovidonum, silica colloidalis anhydrica, sorbitani lauras, calcii hydrogenophosphas, natrii stearylis fumaras, Überzug: hypromellosum, e 171, macrogolum 400, macrogolum 3350, hydroxypropylcellulosum, talcum, silica colloidalis anhydrica, polysorbatum 80, pro compresso obducto, natrium 0.388 mg. - behandlung von covid-19 - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - ritonavirum - compresse rivestite con film - ritonavirum 100 mg, copovidonum k 28, sorbitani lauras, silica colloidalis anhydrica, natrii stearylis fumaras corresp. natrium 0.135 mg, calcii hydrogenophosphas, Überzug: hypromellosum, macrogolum 400, hydroxypropylcellulosum, talcum, silica colloidalis anhydrica, macrogolum 3350, polysorbatum 80, e 171, pro compresso obducto. - le infezioni da hiv - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

axapharm ag - itraconazolum - capsule - kapsel: itraconazolum 100 mg, saccharomonospora, spherae 195 mg, hypromellosum, sorbitani stearas, silice colloidalis hydrica, kapselhülle: gelatina, e-171, e 172 (rubrum), pro capsula. - antifungini - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

aspen pharma trading limited - digossina - digossina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - ritonavir - ritonavir